Puma Biotechnology (NYSE: PBYI) recently received a number of ratings updates from brokerages and research firms:

  • 7/11/2017 – Puma Biotechnology was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Puma Biotechnology shares soared recently after an FDA advisory committee recommended approval of its lead pipeline candidate, neratinib for the treatment of HER2-positive breast cancers. As a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, the company is totally dependent on its lead candidate neratinib for growth. With the latest FDA panel win, the approval of neratinib seems high. An approval would be a huge boost for the company given the immense commercial potential in the target market. However, dependence on the successful development and of a single candidate may severely hurt the company’s growth prospects in case of any adverse development or regulatory setback. Shares of the company have outperformed the industry in the past one year.”
  • 7/10/2017 – Puma Biotechnology had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $115.00 price target on the stock.
  • 7/10/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $105.00 price target on the stock.
  • 6/30/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $105.00 price target on the stock.
  • 6/14/2017 – Puma Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Puma Biotechnology shares soared recently after an FDA advisory committee recommended approval of its lead pipeline candidate, neratinib for the treatment of HER2-positive breast cancers. As a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, the company is totally dependent on its lead candidate neratinib for growth. With the latest FDA panel win, the approval of neratinib seems high. An approval would be a huge boost for the company given the immense commercial potential in the target market. However, dependence on the successful development and of a single candidate may severely hurt the company’s growth prospects in case of any adverse development or regulatory setback. Shares of the company have outperformed the industry in the past one year.”
  • 6/8/2017 – Puma Biotechnology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $89.00 price target on the stock. According to Zacks, “Puma Biotechnology shares soared recently after an FDA advisory committee recommended approval of its lead pipeline candidate, neratinib for the treatment of HER2-positive breast cancers. As a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, the company is totally dependent on its lead candidate neratinib for growth. With the latest FDA panel win, the approval of neratinib seems highly likely. An approval would be a huge boost for the company given the immense commercial potential in the target market. However, dependence on the successful development and of a single candidate may severely hurt the company’s growth prospects in case of any adverse development or regulatory setback. Shares of the company have outperformed the industry in the past one year.”
  • 6/7/2017 – Puma Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Puma Biotechnology shares soared recently after an FDA advisory committee recommended approval of its lead pipeline candidate, neratinib for the treatment of HER2-positive breast cancers. As a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, the company is totally dependent on its lead candidate neratinib for growth. With the latest FDA panel win, the approval of neratinib seems highly likely. An approval would be a huge boost for the company given the immense commercial potential in the target market. However, dependence on the successful development and of a single candidate may severely hurt the company’s growth prospects in case of any adverse development or regulatory setback. Shares of the company have outperformed the industry in the past one year.”
  • 6/6/2017 – Puma Biotechnology had its price target raised by analysts at Royal Bank Of Canada from $60.00 to $88.00. They now have a “sector perform” rating on the stock.
  • 6/6/2017 – Puma Biotechnology had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $89.00 price target on the stock.
  • 6/5/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $105.00 price target on the stock.
  • 5/28/2017 – Puma Biotechnology was upgraded by analysts at Citigroup Inc. to a “buy” rating. They now have a $105.00 price target on the stock.
  • 5/25/2017 – Puma Biotechnology had its price target raised by analysts at Royal Bank Of Canada from $40.00 to $60.00. They now have a “sector perform” rating on the stock.
  • 5/25/2017 – Puma Biotechnology had its price target raised by analysts at Bank of America Corporation from $72.00 to $86.00. They now have a “buy” rating on the stock.
  • 5/25/2017 – Puma Biotechnology was upgraded by analysts at Cowen and Company from a “neutral” rating to an “outperform” rating. They now have a $91.00 price target on the stock.
  • 5/25/2017 – Puma Biotechnology had its price target raised by analysts at Credit Suisse Group from $58.00 to $90.00. They now have an “outperform” rating on the stock.
  • 5/24/2017 – Puma Biotechnology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $59.00 price target on the stock. According to Zacks, “Puma Biotechnology reported narrower-than-expected loss in the first quarter of 2017. As a development-stage company, it does not have any approved product in its portfolio yet. Thus, the company is totally dependent on its lead candidate neratinib for growth. The candidate is currently under review in both the U.S. and the EU for the treatment of HER2-positive breast cancer. An approval would be a huge boost for the company given the immense commercial potential in the target market. However, such dependence on the successful development and of a single candidate may severely hurt the company’s growth prospects in case of any adverse development or regulatory setback. Shares of the company have outperformed the industry in the past one year.”
  • 5/24/2017 – Puma Biotechnology had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $89.00 price target on the stock.
  • 5/23/2017 – Puma Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Puma Biotechnology reported narrower-than-expected loss in the first quarter of 2017. As a development-stage company, it does not have any approved product in its portfolio yet. Thus, the company is totally dependent on its lead candidate neratinib for growth. The candidate is currently under review in both the U.S. and the EU for the treatment of HER2-positive breast cancer. An approval would be a huge boost for the company given the immense commercial potential in the target market. However, such dependence on the successful development and of a single candidate may severely hurt the company’s growth prospects in case of any adverse development or regulatory setback. Shares of the company have outperformed the industry in the past one year.”
  • 5/22/2017 – Puma Biotechnology was given a new $58.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 5/22/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $88.00 price target on the stock.
  • 5/22/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $88.00 price target on the stock.
  • 5/22/2017 – Puma Biotechnology had its “market perform” rating reaffirmed by analysts at Cowen and Company.

Shares of Puma Biotechnology Inc (NYSE PBYI) traded down 3.85% during trading on Monday, reaching $86.10. 690,767 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $70.29 and its 200 day moving average price is $44.73. The firm’s market capitalization is $3.18 billion. Puma Biotechnology Inc has a 52 week low of $28.35 and a 52 week high of $94.70.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. Analysts predict that Puma Biotechnology Inc will post ($8.44) EPS for the current fiscal year.

In other Puma Biotechnology news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of Puma Biotechnology stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $75.38, for a total value of $93,147,066.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Richard Paul Bryce sold 5,000 shares of Puma Biotechnology stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $87.10, for a total value of $435,500.00. Following the completion of the sale, the senior vice president now owns 34,237 shares of the company’s stock, valued at $2,982,042.70. The disclosure for this sale can be found here. Insiders sold 1,995,088 shares of company stock worth $157,988,613 over the last ninety days. 22.70% of the stock is currently owned by insiders.

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.